In the beginning of CD19-CAR-T cell therapy, it was observed that patients with a higher leukemia burden would facilitate a better engraftment of CD19-CAR-T cells and thus CAR T cell therapy would be more successful. The gene discussed is CD19; the disease is leukemia.